Expiry of Unlisted Options
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
10 March 2026
Expiry of Unlisted Options
Biome Australia Limited (ASX: BIO) advises that 625,000 unlisted options
exercisable at $0.12, 2,250,000 unlisted options exercisable at $0.20 and
2,500,000 unlisted options exercisable at $0.50 per option are due to expire at
5:00pm (EDST) on 31 March 2026.
Each option entitles the holder to subscribe for one fully paid ordinary share in
the Company.
Option holders wishing to exercise their options must ensure that a valid notice
of exercise together with payment of the applicable exercise price is received
by the Company no later than 5:00pm (EDST) on 31 March 2026.
Any options not exercised by this time will automatically lapse in accordance
with their terms of issue.
If all options are exercised, the Company will issue 4,750,000 fully paid ordinary
shares and receive approximately $1,775,000 in funds.
The latest closing price of the Company’s shares on ASX prior to this
announcement was $0.40.
The Company confirms that written notice has been provided to option holders
in accordance with the terms of issue of the options.
-ENDS-
Approved for release by the Biome Australia Limited Board of Directors.
About Biome Australia Limited
Biome Australia develops, licenses, commercialises and markets innovative, evidence-
based live biotherapeutics (probiotics) and complementary medicines, many of which
are supported by clinical research. Biome aims to improve health outcomes and quality
of life, and make its products accessible to all.
Incorporated in Australia in 2018, Biome distributes locally and abroad. In partnership
with some of the world's leading organisations in microbiome research and
development, Biome produced several unique live biotherapeutic (probiotic) products
with innovative delivery technologies that improve their stability and efficacy to create
its flagship range of complementary medicines: Activated Probiotics®
.
Supported by clinical research, including randomised double-blind placebo-controlled
trials, Activated Probiotics help prevent and support the management of various health
concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema
and IBS. Through practitioner-only distribution, Biome is committed to educating
health professionals on the newfound systemic health effects of the gut microbiota,
helping them to provide innovative, evidence-based natural medicines for the
management of some of humanity's most prevalent and chronic health concerns.
For more information visit: www.biomeaustralia.com
Investor Relations
Lauren Dwyer - CFO
corporate@biomeaustralia.com
Media enquiries
media@activated.co
Share your feedback
Discover